Wolters Kluwer puts Adis on block

Share this article:

Wolters Kluwer said it will divest its Pharma Solutions business unit, in two parts.

Brands now on the block include the PHAST syndicated prescription data service, plus the Adis R&D Insight and inThought pipeline analysis tools. 

Pharma Solutions “no longer fits with the [company] growth strategy,” which is to focus spending and investment in core healthcare provider markets, Robert Dekker, VP of communications for Wolters Kluwer Health & Pharma Solutions, told MM&M.

Health brands that are staying include the Lippincott Williams & Wilkins textbooks and journals, and UpToDate web and mobile medical apps.

Officials expect to close a sale around, or shortly after, year's end. William Blair & Co. and Lazard Middle Market have been retained as advisors for separate sell-offs of the healthcare analytics and marketing & publishing services businesses, respectively.

Share this article:
close

Next Article in Agency Gallery

Email Newsletters

More in Agency Gallery

Private View: Creating Compelling Experiences

Private View: Creating Compelling Experiences

In today's multi-channel environment, game-changing ideas blend creativity and sensory ideation to create a meaningful customer experience

Putting consumers at the center of your universe

Putting consumers at the center of your universe

The question should be: How do you simplify and identify the moments that mean the most to customers?

Did "pay-to-play" confab help Zohydro approval?

Did "pay-to-play" confab help Zohydro approval?

US senators Joe Manchin (D-WV) and David Vitter (R-LA) are asking whether a "pay-to-play" meeting between drug industry executives and FDA officials influenced the agency's approval of Zohydro